Title of the cohort

Northern Ireland Study of Health and Stress

Acronym for cohort


Name of Principal Investigator
First nameBrendan
Last nameBunting
Address of institution where award is held
InstitutionUniversity of Ulster
Street AddressCollege Avenue
PostcodeBT48 7JL
  • United Kingdom

www.science.ulster.ac.uk/research/psychology/nishs/ –

Contact email
Funding source

Public Health Agency for Northern Ireland, Research and Development Office

1. The cohort includes, or expects to include, incidence of the following conditions
  • Neurodegenerative disease in general
When studies on the above condition(s) are expected to become possible
2a. Stated aim of the cohort

To establish the prevalence and correlates of mental health using DSM and ICD criteria.

2b. Features distinguishing this cohort from other population cohorts

Unique within Northern Ireland, but linked to similar datasets in other countries.

3a. i) Number of publications that involve use of cohort to date
3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)
3b. Publication list/link to where data or publications are accessible (if available)

1. Ferry, F., Bolton, D., Bunting, B., Devine, B., McCann, S. & Murphy, S. (2008). Trauma, Health and Conflict in Northern Ireland. ISBN 978-1-85923-228-6.

2. Kessler et al (in press). Treated and untreated prevalence of mental disorders: Results from the World Health Organization World Mental Health (WMH) Surveys. Oxford Textbook of Community Mental Health and edited by Professor Graham Thornicroft, Professor George Szmukler, Dr Kim Mueser, and Dr Robert Drake. Oxford Press.

3c. Information (i.e. research findings) expected to be gained from the population cohort

Prevalence, severity, comorbidity, age-of-onset, service use, failure and delays in treatment and dropout from treatment services, based on 30 days, 12 months, and lifetime.

4a. Study criteria: age range of participants at recruitment
Age in years from:18+ years
To (‘until death’ if applicable):
4b. Study criteria: inclusion criteria

Individuals living in the community

4c. Study criteria: exclusion criteria


5. Size of the cohort (i.e. number of participants enrolled)
  • 1,000 – 5,000 participants
6a. Measures used to characterise participants

DSM and ICD criteria as evaluated using the CIDI.

6b. Additional measures for participants with a clinical disorder


6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)
  • No
7. Study design
  • Cross sectional survey
8. Cases matched by
  • Co-morbidities
9a. Does the study include a specialised subset of control participants
  • Yes
9b. If yes, description of specialised subset of control participants

One hundred percent of those who sceened for a condition were included in the long form of the interview, as were 50% of those meeting a ‘subthreshold’ core disorder, and 25% of the remaining sample.

10a. i) Data collection start date


10a. ii) Data collection end date


10a iii) Data collection for this study is
  • Closed to new patients
10b. Plans to continue the cohort study beyond the current projected end date
  • Yes – funding applied for
11. Data collected
  • Only through the study
12. System in place to enable re-contact with patients for future studies
  • Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)
13a. Format and availability of data stored in a database
Yes/No% available
Data summarised in database Yes
Database is web-based
Database on spreadsheet Yes
Database is on paper
Other (specify)


Language used:


13b. Format and availability of data held as individual records
Yes/No% available
Data held as individual records Yes
Data is web-based
Data held on computer based records Yes
Data held on cards
Other (specify)


Language used:


14a. Are data available to other groups


14b. Access policy/mechanisms for access if data are available to other groups
  • Access through collaboration with PI only
15. Data sharing policy specified as a condition of use
  • No requirement to make data publicly available
16a. Are tissues/samples/DNA available to other groups


16b. i) Description of available tissues/samples/DNA
16b. ii) Form available tissues/samples/DNA are supplied in
16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data
17. Is information on biological characteristics available to other groups
  • No

    Types: Population Cohorts
    Member States: United Kingdom
    Diseases: Neurodegenerative disease in general
    Years: 2011
    Database Categories: N/A
    Database Tags: N/A

    Export as PDF